Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
A limited list of criteria for selection of participants in the clinical study, provided in terms of inclusion and exclusion criteria and suitable for assisting potential participants in identifying clinical studies of interest. Use a bulleted list for each criterion below the headers Inclusion Criteria and Exclusion Criteria. (Limit: 15,000 characters.) Inclusion criteria~1. Males and females ≥ 18 and ≤ 80 years of age;~2. LDL_C during screening period met the following conditions: super high risk: LDL - C ≥1.4mmol/L (55 mg/dL); extremely high risk: LDL - C ≥1.8 mmol/L (70 mg/dL); risk: LDL - C ≥2.6 mmol/L (100 mg/dL); low risk: LDL - C ≥ 3.4 /mmol/L (130 mg/dL)~3. Fasting triglycerides ≤4.5 mmol/L;~Exclusion criteria~1. Known HoFH;~2. History of NYHA class III-IV heart failure;~3. History of uncontrolled arrhythmia, Unstable angina,MI, PCI,CABG, DVT or pulmonary embolism within 3 months.~4. Uncontrolled hypertension.~5. Uncontrolled diabetes mellitius (HbA1c\>8.0%）.~6. Other conditions that investigators considered inappropriate to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- JS002 (Type: EXPERIMENTAL): Cohort 1: 150 mg/1mL Q2W Subcutaneous(SC); Cohort 2: 300/2mL mg Q4W Subcutaneous(SC);
- Placebo (Type: PLACEBO_COMPARATOR): Cohort 1: 1mL Q2W Subcutaneous(SC); Cohort 2: 2mL Q4W Subcutaneous(SC);

Based on this trial design, predict the completion outcome and termination type (if applicable).